Leerink Partners Initiates Coverage On Phathom Pharmaceuticals with Market Perform Rating, Announces Price Target of $10

Benzinga Newsdesk www.benzinga.com Positive 55.7%

Neg 0% Neu 0% Pos 55.7%

Leerink Partners analyst Daniel Clark initiates coverage on Phathom Pharmaceuticals (NASDAQ:PHAT) with a Market Perform rating and announces Price Target of $10.